Antengene's (HKG:6996) Chief Financial Officer Donald Andrew Lung resigned effective Aug. 1 to pursue other career opportunities, according to a Friday Hong Kong bourse filing.
Separately, the cancer therapy developer named Rui Guo as its chief business officer with effect from the same day. Guo has been a part of the Company since 2017.